GLP ‐1 receptor activated insulin secretion from pancreatic β‐cells: mechanism and glucose dependence

Abstract

The major goal in the treatment of type 2 diabetes mellitus is to control the hyperglycaemia characteristic of the disease. However, treatment with common therapies such as insulin or insulinotrophic sulphonylureas ( SU ), while effective in reducing hyperglycaemia, may impose a greater risk of hypoglycaemia, as neither therapy is self‐regulated by ambient blood glucose concentrations. Hypoglycaemia has been associated with adverse physical and psychological outcomes and may contribute to negative cardiovascular events; hence minimization of hypoglycaemia risk is clinically advantageous. Stimulation of insulin secretion from pancreatic β‐cells by glucagon‐like peptide 1 receptor ( GLP‐1R ) agonists is known to be glucose‐dependent. GLP‐1R agonists potentiate glucose‐stimulated insulin secretion and have little or no activity on insulin secretion in the absence of elevated blood glucose concentrations. This ‘glucose‐regulated’ activity of GLP‐1R agonists makes them useful and potentially safer therapeutics for overall glucose control compared to non‐regulated therapies; hyperglycaemia can be reduced with minimal hypoglycaemia. While the inherent mechanism of action of GLP‐1R agonists mediates their glucose dependence, studies in rats suggest that SUs may uncouple this dependence. This hypothesis is supported by clinical studies showing that the majority of events of hypoglycaemia in patients treated with GLP‐1R agonists occur in patients treated with a concomitant SU . This review aims to discuss the current understanding of the mechanisms by which GLP ‐1R signalling promotes insulin secretion from pancreatic β‐cells via a glucose‐dependent process.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 97

1. 1.

   DeFronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773-795.

   Not in our library10.2337/db09-9028

2. 2.

   Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1577-1596.

   Not in our library10.1007/s00125-012-2534-0

3. 3.

   Pettersson B, Rosenqvist U, Deleskog A, Journath G, Wändell P. Self-reported experience of hypoglycemia among adults with type 2 diabetes mellitus (Exhype). Diabetes Res Clin Pract. 2011;92:19-25.

   Not in our library10.1016/j.diabres.2010.12.005

4. 4.

   Christensen TF, Randløv J, Kristensen LE, Eldrup E, Hejlesen OK, Struijk JJ. QT measurement and heart rate correction during hypoglycemia: is there a bias? Cardiol Res Pract. 2010;2010:961290.

   Not in our library10.4061/2010/961290

5. 5.

   Eckert B, Agardh CD. Hypoglycaemia leads to an increased QT interval in normal men. Clin Physiol. 1998;18:570-575.

   Not in our library10.1046/j.1365-2281.1998.00138.x

6. 6.

   Meinhold J, Heise T, Rave K, Heinemann L. Electrocardiographic changes during insulin-induced hypoglycemia in healthy subjects. Horm Metab Res. 1998;30:694-697.

   Not in our library10.1055/s-2007-978960

7. 7.

   Johnston SS, Conner C, Aagren M, Smith DM, Bouchard J, Brett J. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Care. 2011;34:1164-1170.

   Not in our library10.2337/dc10-1915

8. 8.

   Yakubovich N, Gerstein HC. Serious cardiovascular outcomes in diabetes: the role of hypoglycemia. Circulation. 2011;123:342-348.

   Not in our library10.1161/circulationaha.110.948489

9. 9.

   Cryer PE. Death during intensive glycemic therapy of diabetes: mechanisms and implications. Am J Med. 2011;124:993-996.

   Not in our library10.1016/j.amjmed.2011.08.008

10. 10.

    Leech CA, Dzhura I, Chepurny OG, et al. Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic β cells. Prog Biophys Mol Biol. 2011;104:236-247.

    Not in our library10.1016/j.pbiomolbio.2011.07.005

11. 11.

    Hui H, Farilla L, Merkel P, Perfetti R. The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. Eur J Endocrinol. 2002;146:863-869.

    Not in our library10.1530/eje.0.1460863

12. 12.

    Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131-2157.

    Not in our library10.1053/j.gastro.2007.03.054

13. 13.

    Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008;60:470-512.

    Not in our library10.1124/pr.108.000604

14. 14.

    Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care. 2011;34(Suppl 2):S279-S284.

    Not in our library10.2337/dc11-s231

15. 15.

    Apovian CM, Bergenstal RM, Cuddihy RM, et al. Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. Am J Med. 2010;123:468.e9-468.e17.

    Not in our library10.1016/j.amjmed.2009.11.019

16. 16.

    Bergenstal RM, Wysham C, MacConell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376:431-439.

    Not in our library10.1016/s0140-6736(10)60590-9

17. 17.

    Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96:1301-1310.

    Not in our library10.1210/jc.2010-2081

18. 18.

    Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375:2234-2243.

    Not in our library10.1016/s0140-6736(10)60406-0

19. 19.

    Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372:1240-1250.

    Not in our library10.1016/s0140-6736(08)61206-4

20. 20.
    Liraglutide, a once‐daily human glucagon‐like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes · 2011

    No notice
21. 21.

    Liutkus J, Rosas Guzman J, Norwood P, et al. A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin. Diabetes Obes Metab. 2010;12:1058-1065.

    Not in our library10.1111/j.1463-1326.2010.01251.x

22. 22.

    Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32:84-90.

    Not in our library10.2337/dc08-1355

23. 23.

    Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia. 2009;52:2046-2055.

    Not in our library10.1007/s00125-009-1472-y

24. 24.

    Esposito K, Mosca C, Brancario C, Chiodini P, Ceriello A, Giugliano D. GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Curr Med Res Opin. 2011;27:1519-1528.

    Not in our library10.1185/03007995.2011.590127

25. 25.

    Creutzfeldt W. Insulinotropic factors of the gut—the broadening incretin concept. Gastroenterology. 1980;78:1631-1632.

    Not in our library

26. 26.

    Creutzfeldt W, Ebert R. New developments in the incretin concept. Diabetologia. 1985;28:565-573.

    Not in our library10.1007/bf00281990

27. 27.

    Fridolf T, Böttcher G, Sundler F, Ahrén B. GLP-1 and GLP-1(7–36) amide: influences on basal and stimulated insulin and glucagon secretion in the mouse. Pancreas. 1991;6:208-215.

    Not in our library

28. 28.

    Göke R, Wagner B, Fehmann HC, Göke B. Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7-36) amide on the rat pancreas. Res Exp Med (Berl). 1993;193:97-103.

    Not in our library10.1007/bf02576216

29. 29.

    Nauck MA, Sauerwald A, Ritzel R, Holst JJ, Schmiegel W. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Diabetes Care. 1998;21:1925-1931.

    Not in our library10.2337/diacare.21.11.1925

30. 30.

    Qualmann C, Nauck MA, Holst JJ, Orskov C, Creutzfeldt W. Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects. Acta Diabetol. 1995;32:13-16.

    Not in our library10.1007/bf00581038

31. 31.

    Degn KB, Brock B, Juhl CB, et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes. 2004;53:2397-2403.

    Not in our library10.2337/diabetes.53.9.2397

32. 32.

    Baggio L, Adatia F, Bock T, Brubaker PL, Drucker DJ. Sustained expression of exendin-4 does not perturb glucose homeostasis, β-cell mass, or food intake in metallothionein-preproexendin transgenic mice. J Biol Chem. 2000;275:34471-34477.

    Not in our library10.1074/jbc.m005119200

33. 33.

    Montrose-Rafizadeh C, Egan JM, Roth J. Incretin hormones regulate glucose-dependent insulin secretion in RIN 1046-38 cells: mechanisms of action. Endocrinology. 1994;135:589-594.

    Not in our library10.1210/endo.135.2.8033807

34. 34.

    Egan JM, Clocquet AR, Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab. 2002;87:1282-1290.

    Not in our library10.1210/jcem.87.3.8337

35. 35.

    Linnebjerg H, Park S, Kothare PA, et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept. 2008;151:123-129.

    Not in our library10.1016/j.regpep.2008.07.003

36. 36.

    Russell-Jones D, Cuddihy RM, Hanefeld M, et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care. 2012;35:252-258.

    Not in our library10.2337/dc11-1107

37. 37.

    Vilsbøll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007;30:1608-1610.

    Not in our library10.2337/dc06-2593

38. 38.

    DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092-1100.

    Not in our library10.2337/diacare.28.5.1092

39. 39.

    Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2008;30:1448-1460.

    Not in our library10.1016/j.clinthera.2008.08.006

40. 40.

    Zinman B, Hoogwerf BJ, Durán García S, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2007;146:477-485.

    Not in our library10.7326/0003-4819-146-7-200704030-00003

Cited by papers we hold 11

• The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis · 2022
  Not checked
• L‐arginine as a potential GLP‐1‐mediated immunomodulator of Th17‐related cytokines in people with obesity and asthma · 2021
  Not checked
• The metabolic impact of small intestinal nutrient sensing · 2021
  No notice
• Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases · 2019
  No notice
• The Short-Chain Fatty Acid Acetate in Body Weight Control and Insulin Sensitivity · 2019
  No notice
• Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial · 2018
  No notice
• Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function · 2018
  No notice
• GLP-1 receptor signalling promotes β-cell glucose metabolism via mTOR-dependent HIF-1α activation · 2017
  No notice
• Microneedle-array patches loaded with dual mineralized protein/peptide particles for type 2 diabetes therapy · 2017
  No notice
• An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass · 2016
  Not checked
• Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects · 2015
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.